Altimmune Inc
NASDAQ:ALT

Watchlist Manager
Altimmune Inc Logo
Altimmune Inc
NASDAQ:ALT
Watchlist
Price: 5.09 USD 1.19% Market Closed
Market Cap: 530.6m USD

Net Margin
Altimmune Inc

-419 575%
Current
-134 872.6%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-419 575%
=
Net Income
-83.9m
/
Revenue
20k

Net Margin Across Competitors

No Stocks Found

Altimmune Inc
Glance View

Market Cap
486.6m USD
Industry
Biotechnology

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

ALT Intrinsic Value
5.78 USD
Undervaluation 12%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-419 575%
=
Net Income
-83.9m
/
Revenue
20k
What is the Net Margin of Altimmune Inc?

Based on Altimmune Inc's most recent financial statements, the company has Net Margin of -419 575%.

Back to Top